1. Home
  2. IDYA vs ARCB Comparison

IDYA vs ARCB Comparison

Compare IDYA & ARCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • ARCB
  • Stock Information
  • Founded
  • IDYA 2015
  • ARCB 1923
  • Country
  • IDYA United States
  • ARCB United States
  • Employees
  • IDYA N/A
  • ARCB N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • ARCB Trucking Freight/Courier Services
  • Sector
  • IDYA Health Care
  • ARCB Industrials
  • Exchange
  • IDYA Nasdaq
  • ARCB Nasdaq
  • Market Cap
  • IDYA 1.9B
  • ARCB 1.6B
  • IPO Year
  • IDYA 2019
  • ARCB N/A
  • Fundamental
  • Price
  • IDYA $20.79
  • ARCB $77.16
  • Analyst Decision
  • IDYA Strong Buy
  • ARCB Buy
  • Analyst Count
  • IDYA 13
  • ARCB 13
  • Target Price
  • IDYA $53.42
  • ARCB $92.92
  • AVG Volume (30 Days)
  • IDYA 1.1M
  • ARCB 356.6K
  • Earning Date
  • IDYA 08-05-2025
  • ARCB 08-01-2025
  • Dividend Yield
  • IDYA N/A
  • ARCB 0.63%
  • EPS Growth
  • IDYA N/A
  • ARCB 50.16
  • EPS
  • IDYA N/A
  • ARCB 7.55
  • Revenue
  • IDYA $7,000,000.00
  • ARCB $4,109,676,999.00
  • Revenue This Year
  • IDYA $101.20
  • ARCB $0.24
  • Revenue Next Year
  • IDYA $286.70
  • ARCB $6.18
  • P/E Ratio
  • IDYA N/A
  • ARCB $10.04
  • Revenue Growth
  • IDYA N/A
  • ARCB N/A
  • 52 Week Low
  • IDYA $13.45
  • ARCB $55.19
  • 52 Week High
  • IDYA $44.42
  • ARCB $129.83
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 62.23
  • ARCB 68.82
  • Support Level
  • IDYA $21.08
  • ARCB $67.83
  • Resistance Level
  • IDYA $22.37
  • ARCB $74.63
  • Average True Range (ATR)
  • IDYA 0.92
  • ARCB 2.54
  • MACD
  • IDYA -0.09
  • ARCB 0.77
  • Stochastic Oscillator
  • IDYA 61.72
  • ARCB 92.00

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About ARCB ArcBest Corporation

ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.

Share on Social Networks: